Journal of the American Academy of Dermatology
Volume 62, Issue 3 , Pages 486-488 , March 2010

Hormone therapy for acne

  • Jacqueline M. Junkins-Hopkins, MD

      Affiliations

    • Corresponding Author InformationReprint requests: Jacqueline M. Junkins-Hopkins, MD, Division of Dermatopathology and Oral Pathology, Department of Dermatology, Johns Hopkins Medical Institution, 601 N Wolfe St, Blalock 9, Baltimore, MD 21287.

References 

  1. George R, Clarke S, Thiboutot D. Hormonal therapy for acne. Semin Cutan Med Surg. 2008;27:188–196
  2. Bhambri S, Del Rosso JQ, Bhambri A. Pathogenesis of acne vulgaris: recent advances. J Drugs Dermatol. 2009;8:615–618
  3. McInturff JE, Kim J. The role of toll-like receptors in the pathophysiology of acne. Semin Cutan Med Surg. 2005;24:73–78
  4. Ganceviciene R, Graziene V, Fimmel S, Zouboulis CC. Involvement of the corticotropin-releasing hormone system in the pathogenesis of acne vulgaris. Br J Dermatol. 2009;160:345–352
  5. Karrer-Voegeli S, Rey F, Reymond MJ, Meuwly JY, Gaillard RC, Gomez F. Androgen dependence of hirsutism, acne, and alopecia in women: retrospective analysis of 228 patients investigated for hyperandrogenism. Medicine (Baltimore). 2009;88:32–45
  6. Brown J, Farquhar C, Lee O, Toomath R, Jepson RG. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database Syst Rev. 2009;2:CD000194
  7. Arowojolu AO, Gallo MF, Lopez LM, Grimes DA, Garner SE. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev. 2009;3:CD004425
  8. Harper JC. Should dermatologists prescribe hormonal contraceptives for acne?. Dermatol Ther. 2009;22:452–457
  9. Fenton C, Wellington K, Moen MD, Robinson DM. Drospirenone/ethinylestradiol 3mg/20microg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris. Drugs. 2007;67:1749–1765
  10. Mishell DR. YAZ and the novel progestin drospirenone. J Reprod Med. 2008;53(9 suppl):721–728

 The statements and opinions expressed in this commentary are those of the Editor-in-Chief of Dialogues in Dermatology.

 Funding sources: None.

 Disclosure: Drs Junkins-Hopkins, Stone, and Harper have no conflicts of interest to declare.

PII: S0190-9622(09)02211-7

doi: 10.1016/j.jaad.2009.12.002

Journal of the American Academy of Dermatology
Volume 62, Issue 3 , Pages 486-488 , March 2010

Article Tools